度洛西汀的肝脏安全性概况：综述
The hepatic safety profile of duloxetine: a review.
作者信息
McIntyre Roger S, Panjwani Zilomi D, Nguyen Ha T, Woldeyohannes Hanna O, Alsuwaidan Mohammad, Soczynska Joanna K, Lourenco Maria T, Konarski Jakub Z, Kennedy Sidney H
机构信息
University Health Network, Mood Disorders Psychopharmacology Unit, 399 Bathurst Street, Toronto, ON, M5T 2S8, Canada.
出版信息
Expert Opin Drug Metab Toxicol. 2008 Mar;4(3):281-5. doi: 10.1517/17425255.4.3.281.
BACKGROUND
Hepatotoxicity related to the use of duloxetine resulted in rewording of the US product insert.
OBJECTIVE
To characterize the hepatic safety profile of duloxetine.
METHODS
We conducted a PubMed search of all English-language articles published between January 1990 and December 2007 and contacted the manufacturer (Eli Lilly, Inc.).
RESULTS
Elevations of alanine aminotransferase to three times the upper limit of normal occurs in 0.9-1.7% of duloxetine-treated patients versus 0.0-0.3% of placebo-treated patients. Hepatocellular, cholestatic and mixed hepatocellular-cholestatic forms of hepatic injury have been described.
CONCLUSION
Duloxetine does not appear to pose a greater hazard for hepatic toxicity when compared to other conventional antidepressants. Systematic monitoring of liver aminotransferases does not appear to be warranted with routine duloxetine use.
背景
与度洛西汀使用相关的肝毒性导致美国药品说明书措辞的修改。
目的
描述度洛西汀的肝脏安全性概况。
方法
我们对1990年1月至2007年12月发表的所有英文文章进行了PubMed检索，并联系了制造商（礼来公司）。
结果
接受度洛西汀治疗的患者中，丙氨酸氨基转移酶升高至正常上限3倍的发生率为0.9 - 1.7%，而接受安慰剂治疗的患者为0.0 - 0.3%。已经描述了肝细胞性、胆汁淤积性和混合性肝细胞 - 胆汁淤积性肝损伤形式。
结论
与其他传统抗抑郁药相比，度洛西汀似乎不会对肝毒性构成更大风险。常规使用度洛西汀时，似乎没有必要对肝脏转氨酶进行系统监测。
Zotero 插件